Clinical Trials Logo

Clinical Trial Summary

Neoadjuvant chemotherapy is frequently proposed to patients with mammary gland cancer. The aim is to reduce tumor volume before surgical therapy. Obtaining a pathologic Complete Response (pCR) is regarded as a good prognostic factor with less risk of recurrence. The rate of pCR is about 20%, although there are important variations according to tumor subtype and the type of treatment. The objective of the new therapeutic strategies is to increase this response rate. The purpose of this study is to investigate the possibility of early evaluation of neoadjuvant chemotherapy response after one cycle of neoadjuvant chemotherapy by positron emission tomography (PET) with (18) F-fluorodeoxyglucose (FDG) in patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02386709
Study type Interventional
Source Centre Georges Francois Leclerc
Contact
Status Active, not recruiting
Phase N/A
Start date March 25, 2015
Completion date March 25, 2028